He Dongning, Wang Wenjuan, Luo Xigang, Wang Yadi
Medical Oncology of The Third Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, China.
Rehabilitation Department of The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, China.
Front Pharmacol. 2025 Aug 20;16:1616162. doi: 10.3389/fphar.2025.1616162. eCollection 2025.
Epirubicin, a widely used anthracycline, effectively treats various cancers but poses a high risk of cardiotoxicity, leading to heart failure and myocardial dysfunction. This study conducts a cluster analysis to map global research trends in epirubicin-induced cardiotoxicity.
A literature search was conducted using the Web of Science Core Collection database. Bibliometric tools, including VOSviewer, CiteSpace, and R package "bibliometrix", were employed.
A total of 673 studies were included in the analysis. Italy, China, and the United States led in publication volume. Unicancer was the most prolific institution. Key research was published in high-impact journals such as and P.F. Conte, J.W. Hopewell, and B. Salvadori were the most influential authors. Cluster analysis identified four research hotspots: mechanisms of cardiotoxicity, clinical applications of chemotherapy regimens, combination therapies and pharmacokinetics, formulation advancements and cardioprotective strategies. In addition, there is a clear cut-off among the strongest citation bursts, with the period from 2004-2013 primarily concentrated on disease treatment. From 2014 onwards, the last 10 years have focused on cardiotoxicity and the underlying mechanisms of cardiotoxicity.
This bibliometric study, based on cluster analysis, identified four research hotspots including mechanisms of cardiotoxicity, clinical applications of chemotherapy regimens, combination therapies and pharmacokinetics, formulation advancements and cardioprotective strategies. Future research directions should prioritize the development of AI-driven risk prediction models, integration of multi-omics biomarkers into clinical workflows, and establishment of international cardio-oncology consortiums to enhance personalized cardioprotective strategies and optimize patient outcomes.
表柔比星是一种广泛使用的蒽环类药物，可有效治疗多种癌症，但具有较高的心脏毒性风险，可导致心力衰竭和心肌功能障碍。本研究进行聚类分析以描绘表柔比星诱导的心脏毒性的全球研究趋势。
使用科学网核心合集数据库进行文献检索。采用了文献计量学工具，包括VOSviewer、CiteSpace和R包“bibliometrix”。
分析共纳入673项研究。意大利、中国和美国在发表量方面领先。Unicancer是发表量最多的机构。关键研究发表在如《P.F. Conte》《J.W. Hopewell》和《B. Salvadori》等高影响力期刊上。聚类分析确定了四个研究热点：心脏毒性机制、化疗方案的临床应用、联合治疗和药代动力学、制剂进展和心脏保护策略。此外，在最强的引文爆发之间有一个明显的分界点，2004年至2013年期间主要集中在疾病治疗。从2014年起，过去10年集中在心脏毒性及其潜在机制上。
这项基于聚类分析的文献计量学研究确定了四个研究热点，包括心脏毒性机制、化疗方案的临床应用、联合治疗和药代动力学、制剂进展和心脏保护策略。未来研究方向应优先发展人工智能驱动的风险预测模型，将多组学生物标志物整合到临床工作流程中，以及建立国际心脏肿瘤学联盟，以加强个性化心脏保护策略并优化患者结局。
